Search This Blog

Friday, September 18, 2020

Immunomedics antibody-drug conjugate shows promise v. brain tumors

Immunomedics (NASDAQ:IMMU) announces encouraging Phase 1 data on antibody-drug conjugate Trodelvy (sacituzumab govitecan) (formerly IMMU-132) in patients with brain tumors. The results were virtually presented at ESMO.

At data cutoff, 19 patients were enrolled in the single-center study, 12 with recurrent glioblastoma multiforme (rGBM), the most aggressive type of brain cancer, and seven with brain metastatic breast cancer (BMBC).

Trodelvy delivered 150-fold and 40-fold the 50% inhibitory concentration (IC50) of SN-38, the cytotoxic payload, for BMBC and rGBM, respectively, and produced partial responses in both cohorts.

Progression-free survival (ongoing) was 161-279 days in four BMBC patients and 7-315 days in six rGBM patients.

No new safety signals were observed.

https://seekingalpha.com/news/3615303-immunomedics-antibody-drug-conjugate-shows-encouraging-action-in-brain-tumors

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.